Business Wire

ANT-GROUP

19.4.2022 15:33:12 CEST | Business Wire | Press release

Share
Ant Group Achieves Carbon Neutrality in Its Own Operations With Green Computing Technologies Driving Indirect Emission Cuts

Ant Group today announced it has achieved carbon neutrality in its own operations (Scopes 1 & 2), according to 2021 emission figures certified by the China Environmental United Certification Center (CEC). This marks the Company’s first major step towards fulfilling the commitments it made in March 2021 to achieve net zero in carbon emissions by 2030 , including providing periodic updates on its progress towards achieving this important goal.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220419005649/en/

According to CEC certified figures, in 2021, Ant Group reduced a total of 37,909.87 tons of CO2 e, equivalent to taking 15,000 cars off the road each year, assuming each car is driven 12,000 kilometers per year at 0.203 kilogram of CO2 e per kilometer.

To validate its results, the CEC used Carbon Matrix , AntChain’s software-as-a-service (SaaS) product that helps businesses and institutions track and certify corporate carbon emissions on blockchain. The CEC was an official service provider to the 2022 Winter Olympics, measuring the Olympic Committee’s carbon reduction effectiveness.

In 2021, Ant Group achieved carbon neutrality in its own operations (Scopes 1 & 2) through a combination of reductions, substitutions and offsets:

  • Reduction: reduced 1,668.60 tons of CO2 e by improving its energy savings and efficiency practices.
  • Substitution: avoided 21,883.63 tons of CO2 e through the use of renewable energy.
  • Offset: offset 23,159.54 tons of CO2 e through the purchase of China Certified Emission Reductions (CCERs).

“This is a major milestone since we announced our carbon neutrality goal on March 12, 2021,” said Yijie Peng, Vice President of Ant Group. “Leveraging innovative technologies such as blockchain and green computation, we are well underway to achieve an inclusive, green and sustainable future.”

According to Ant Group’s carbon neutrality roadmap, by 2030, the Company will achieve net zero carbon emissions across Scopes 1, 2 and 3. Scope 1 refers to direct emissions as a result of fossil fuel burning from sources Ant Group owns or controls. Scope 2 refers to indirect emissions associated with the purchase of electricity and the use of heating or cooling networks. Scope 3 refers to all other carbon emissions generated along Ant Group’s value chain, such as the use of data centers, business travel and daily commute programs provided by the Company.

In 2021, Ant Group reduced a total of 36,241.27 tons of CO2 e in Scope 3, of which the adoption of green computing technologies contributed to 29,591.48 tons – or about 82% of all the Scope 3 reduction.

Data centers, which are at the core of today’s digital economy, consume a large amount of electricity and generate considerable carbon emissions. Following the adoption of green computing technologies in 2019 – such as online-offline hybrid deployment, cloud-native time-shared scheduling, AI-based auto scaling and OceanBase enterprise-level distributed relational database – Ant Group more than doubled the utilization rates of data servers in three years, while meaningfully reducing its carbon footprint.

Ant Group’s remaining Scope 3 carbon emission reductions came from sourcing environmentally friendly office supplies, and encouraging employees to take public transportation or shared rides – including taxis and carpooling for local business travel.

The CEC’s carbon neutrality certificate for Ant Group (in Chinese language only) is publicly available on the Information Platform for Carbon Neutrality , which is affiliated with the Environmental Development Center of China’s Ministry of Ecology and Environment.

About Ant Group

Ant Group aims to create the infrastructure and platform to support the digital transformation of the service industry. It strives to enable all consumers and small and micro businesses to have equal access to financial and other services that are inclusive, green and sustainable.

For more information, please visit our website at www.antgroup.com or follow us on Twitter @AntGroup.

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release

New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release

Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release

Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u

Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer Study23.10.2026 13:30:00 CEST | Press release

Data from the Registrational Phase 3 G-HOPE-001 Study of Arcotatug Tavatecan, a Novel, Potential Best-in-Class Claudin (CLDN)18.2 ADC, were Highlighted in a Late-Breaking Presentation at ESMO 2026Arcotatug Tavatecan Met Dual Primary Endpoints of Overall Survival and Progression-Free Survival, Showing Significant Improvements vs. Treatment of Physician’s Choice in Patients with Previously Treated CLDN18.2-Positive Advanced Gastric CancerFindings to Support Planned Regulatory Filing in Japan and Continued Global Development of Arcotatug Tavatecan in CLDN18.2-Positive Cancers Takeda(TSE:4502/NYSE:TAK)announced positive results from the Phase 3 G-HOPE-001 study (NCT06238843) of arcotatug tavatecan (TAK-921; Innovent R&D code: IBI343) in patients with Claudin (CLDN)18.2-positive, previously treated, advanced gastric or gastroesophageal junction adenocarcinoma (G/GEJA). Results from two prespecified interim analyses, which were shared in a late-breaking oral presentation at the 2026 European

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye